Drug news
Baricitinib is filed at FDA to treat rheumatoid arthritis- Eli Lilly + Incyte
Eli Lilly and Company and Incyte Corporation announced that Lilly has submitted a new drug application (NDA) to the FDA for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis (RA).
Comment: Unlike the injected TNF blockers, baricitinib is orally administered. It is a selective JAK1 and JAK2 inhibitor that spares JAK3.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.